Skip to main content
Premium Trial:

Request an Annual Quote

Odyssey Thera, AstraZeneca, Caliper Life Sciences Among Patent Winners


Dan Pankowsky, a professor at Vanderbilt University, has been awarded US Patent No. 6,828,157, “Products and methods for single parameter and multiparameter phenotyping of cells.”

According to its abstract, the patent protects a method of single parameter and multiparameter characterizing of cells, particularly immunophenotyping of cells. The method preferably uses antibody-coated microspheres that are adapted to bind to specific types of cells. One or more sets of coated microspheres are added simultaneously or sequentially to a suspension of cells, and bind the cells they are adapted to bind. Cells may bind to one or more microspheres. The suspension is then filtered to trap bead-cell complexes. The complexes are preferably stained and then examined to characterize the cells, preferably the cells bound to the microspheres. A kit and apparatus for performing the method are also provided, the abstract states.

Odyssey Thera has been awarded US Patent No. 6,828,099, “Protein fragment complementation assay (PCA) for the detection of protein-protein, protein-small molecule, and protein-nucleic acid interactions based on the E. coli TEM-1 beta-lactamase.”

Inventors listed on the patent are Stephen Michnick and Andre Galarneau.

According to its abstract, the patent protects an assay method comprising: (A) generating (1) at least a first fragment of a reporter molecule linked to a first interacting domain, and at least a second fragment of a reporter molecule linked to a second interacting domain, or (2) nucleic acid molecules that code for (A)(1) and subsequently allowing said nucleic acid molecules to produce their coded products; then, (B) allowing interaction of said domains; and (C) detecting reconstituted reporter molecule activity, where said reporter molecule can react with a penicillin- or a cephalosporin-class substrate.

AstraZeneca UK has been awarded US Patent No. 6,828,092, “In vivo assays for modulators of sterol biosynthesis.”

Inventors listed on the patent are Keith Dixon, Peter Broad, and David Scanlon.

According to its abstract, the patent protects a method for identifying agents that modulate sterol biosynthesis. The method comprises contacting a test compound with a host cell comprising a DNA sequence which controls expression of a yeast acetoacetyl CoA thiolase gene operably linked to a reporter system, such that modulation of sterol biosynthesis in the host cell leads to a detectable change in cell phenotype, and determining whether any such detectable change has occurred, the abstract states.

Caliper Life Sciences has been awarded US Patent No. 6,827,831, “Controller/detector interfaces for microfluidic systems.”

Inventors listed on the patent are Calvin Chow, Wallace Parce, Richard McReynolds, Colin Kennedy, and Luc Bousse.

According to its abstract, the patent protects improved methods, structures, and systems for interfacing microfluidic devices with ancillary systems that are used in conjunction with such devices. These systems typically include control and monitoring systems for controlling the performance of the processes carried out within the device, e.g., monitoring and controlling environmental conditions and monitoring results of the processes performed, e.g., detection, the abstract states.


The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.